Effect of vitamin D supplementation on blood pressure in blacks
Forman JP, Scott JB, Ng K, Drake BF, Suarez EG, Hayden DL, Bennett GG, Chandler PD, Hollis BW, Emmons KM, Giovannucci EL, Fuchs CS, Chan AT
Hypertension (Dallas, Tex. : 1979) · 142 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Heart, Lung, and Blood Institute
- Gobierno
- National Cancer Institute
- Gobierno
- NHLBI NIH HHS
- Gobierno
- NCI NIH HHS
- Subvenciones
- National Cancer Institute (P50CA127003); National Cancer Institute (K07CA148894); National Cancer Institute (U01CA138962); National Cancer Institute (K22CA126992); National Heart, Lung, and Blood Institute (R01 HL105440); National Cancer Institute (K05-CA124415); National Cancer Institute (5K05CA124415); National Heart, Lung, and Blood Institute (5R01HL105440)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2013-03-13 · Hypertension · vol. 61 · número 4 · págs. 779–785
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 218 citas · más que el 100% de estudios similares · 23.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 57 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Vitamin D Research Studies · Blood Pressure and Hypertension Studies · Parathyroid Disorders and Treatments
- Palabras clave
- vitamin D supplementation, vitamin D3, blood pressure, African Americans, 25-hydroxyvitamin D, vitamin D deficiency, systolic blood pressure, diastolic blood pressure
- MeSH
- humans, hypertension, cholecalciferol, vitamins, treatment outcome, administration, oral, prevalence, follow-up studies, prospective studies, double-blind method, blood pressure, dose-response relationship, drug, dietary supplements, massachusetts, black or african american
13 autores
- John P. Forman🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Jamil B. Scott🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Kimmie Ng🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Bettina F. Drake🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Elizabeth Gonzalez Suarez🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Douglas L. Hayden🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Gary G. Bennett🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Paulette D. Chandler🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Bruce W. Hollis🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Karen M. Emmons🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Edward L. Giovannucci🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Charles S. Fuchs🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
- Andrew Tan Chan🇺🇸Brigham and Women's Hospital; Harvard University; Medical University of South Carolina; Duke University; Washington University in St. Louis; Massachusetts General Hospital; Dana-Farber Cancer Institute; Dana-Farber Brigham Cancer Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Blacks have significantly higher rates of hypertension than whites, and lower circulating levels of 25-hydroxyvitamin D. There are few data about the effect of vitamin D3 (cholecalciferol) supplementation on blood pressure in blacks. During 2 winters from 2008 to 2010, 283 blacks (median age, 51 years) were randomized into a 4-arm, double-blind trial for 3 months of placebo, 1000, 2000, or 4000 international units of cholecalciferol per day. At baseline, 3 months, and 6 months, systolic and diastolic pressure and 25-hydroxyvitamin D were measured. The 3-month follow-up was completed in 250 (88%) participants. The difference in systolic pressure between baseline and 3 months was +1.7 mm Hg for those receiving placebo, -0.66 mm Hg for 1000 U/d, -3.4 mm Hg for 2000 U/d, and -4.0 mm Hg for 4000 U/d of cholecalciferol (-1.4 mm Hg for each additional 1000 U/d of cholecalciferol; P=0.04). For each 1-ng/mL increase in plasma 25-hydroxyvitamin D, there was a significant 0.2-mm Hg reduction in systolic pressure (P=0.02). There was no effect of cholecalciferol supplementation on diastolic pressure (P=0.37). Within an unselected population of blacks, 3 months of oral vitamin D3 supplementation significantly, yet modestly, lowered systolic pressure. Future trials of vitamin D supplementation on blood pressure are needed to confirm these promising results, particularly among blacks, a population for whom vitamin D deficiency may play a more specific mechanistic role in the pathogenesis of hypertension.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.